HL
Helen Louise Collins sold $234K of ELVN stock
Helen Louise Collins, Chief Medical Officer of Enliven Therapeutics, Inc. (ELVN), sold 5,000 shares of ELVN stock worth $234K, per an SEC Form 4 filed Nov 19, 2026.
The sale was pre-arranged (a 10b5-1 plan or an option exercise), not a fresh decision.
The trade happened on Nov 17, 2026, 2 days before it was made public.
ELVN has moved -0.9% since the trade date, from $46.85 to $46.41 (Nov 19, 2026 close).
- Traded
- Nov 17, 2026
- Disclosed
- Nov 19, 2026
- Filing delay
- 2 days
- Price since
- -0.9%
- Role
- Chief Medical Officer
- Source
- SEC Form 4